The Solution To Antibiotic Resistance – With Cytophage CEO Dr Steven Theriault
FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.
In this interview, Dr. Steven Theriault BSc, MSc, PhD, CEO of Cytophage Technologies Ltd (TSXV: CYTO), sits down with Small Cap Steve to shed light on Cytophage’s groundbreaking work in health science, specifically addressing bacterial infections through tailored bacteriophages. Bacteriophages, viruses that selectively infect and eliminate bacteria, offer an eco-friendly alternative to antibiotics.
Dr. Theriault emphasizes the pressing issue of antibiotic resistance and the critical need for innovative solutions. Cytophage’s technology, spanning human health, animal well-being, and food safety, presents a comprehensive approach. The interview explores the company’s mission to commercialize products globally, potentially revolutionizing bacterial infection treatments on a worldwide scale.
FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
